% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Mattana:271245,
      author       = {F. Mattana and L. Muraglia and P. Raiwa and F. Zattoni and
                      G. Marra and P. K. F. Chiu and I. Heidegger and V.
                      Kasivisvanathan and C. V. Kesch$^*$ and J. Olivier and F.
                      Preisser and C. Thibault and M. Valerio and R. C. N. van den
                      Bergh and G. Gandaglia and F. Ceci},
      collaboration = {E. A. o. U. Y. A. U. P. C. W. Party},
      title        = {{M}etastatic {S}ites' {L}ocation and {I}mpact on {P}atient
                      {M}anagement {A}fter the {I}ntroduction of
                      {P}rostate-specific {M}embrane {A}ntigen {P}ositron
                      {E}mission {T}omography in {N}ewly {D}iagnosed and
                      {B}iochemically {R}ecurrent {P}rostate {C}ancer: {A}
                      {C}ritical {R}eview.},
      journal      = {European urology oncology},
      volume       = {6},
      number       = {2},
      issn         = {2588-9311},
      address      = {Amsterdam},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2023-00377},
      pages        = {128-136},
      year         = {2023},
      note         = {2023 Apr;6(2):128-136},
      abstract     = {The introduction of prostate-specific membrane antigen
                      positron emission tomography (PSMA-PET) had a substantial
                      impact on the management of prostate cancer (PCa) patients
                      with a stage migration phenomenon and consequent treatment
                      changes.To summarise the role of PSMA-PET to define the
                      burden of disease through an accurate location of metastatic
                      site(s) in PCa patients, describing the most common
                      locations at PSMA-PET in the primary staging and recurrence
                      setting, and to assess the clinical impact in the
                      decision-making process.A comprehensive nonsystematic
                      literature review was performed in April 2022. Literature
                      search was updated until March 2022. The most relevant
                      studies have been summarised, giving priority to registered
                      clinical trials and multicentre collaborations.PSMA-PET
                      showed higher diagnostic accuracy than conventional imaging
                      both in newly diagnosed PCa and in recurrent disease. This
                      greater accuracy led to a migration of a higher proportion
                      of patients identified with metastatic disease. Bone
                      metastases were reported as the most frequent site of
                      metastatic spread in staging (up to $17\%)$ and restaging
                      (up to $18\%).$ In staging, considering the suboptimal
                      sensitivity in lymph node metastasis detection prior to
                      radical surgery, PSMA-PET should be performed in patients
                      with high risk or unfavourable intermediate risk only, and
                      it is not recommended to routinely avoid pelvic lymph node
                      dissection in case of a negative scan. In case of
                      prostate-specific antigen relapse, PSMA-PET had higher
                      diagnostic accuracy than other diagnostic procedures in the
                      early detection of the sites of recurrence, thus influencing
                      the therapy decision-making process.PSMA-PET detects a
                      higher number of lesions than conventional imaging or other
                      PET radiotracers, especially metastatic lesions unseen with
                      other modalities. The high diagnostic accuracy of PSMA-PET
                      leads to a significant patient upstage and thus an impact in
                      clinical management, even if the overall impact on cancer
                      mortality is still to be assessed.Prostate-specific membrane
                      antigen positron emission tomography (PSMA-PET) identifies
                      metastatic lesions with higher accuracy than conventional
                      imaging, both in primary prostate cancer and during disease
                      recurrence. Skeletal metastasis and extrapelvic lymph nodes
                      are the most common sites of metastatic spread. The high
                      accuracy of PSMA-PET in the detection of metastatic disease
                      led to a significant impact on patient management, even if
                      the overall impact on cancer mortality is still to be
                      assessed.},
      subtyp        = {Review Article},
      keywords     = {Biochemical recurrence (Other) / Metastatic prostate cancer
                      (Other) / Positron emission tomography (Other) /
                      Prostate-specific membrane antigen (Other) /
                      Prostate-specific membrane antigen prostate cancer (Other)},
      cin          = {ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)ED01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36804735},
      doi          = {10.1016/j.euo.2023.01.014},
      url          = {https://inrepo02.dkfz.de/record/271245},
}